Roché H - Search Results

1

Population pharmacokinetics of carboplatin in children.

Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roché H, Robert A, Newell DR, Canal P. Chatelut E, et al. Among authors: roche h. Clin Pharmacol Ther. 1996 Apr;59(4):436-43. doi: 10.1016/S0009-9236(96)90113-7. Clin Pharmacol Ther. 1996. PMID: 8612389 Clinical Trial.

2

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R. Chatelut E, et al. Among authors: roche h. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80. doi: 10.1093/jnci/87.8.573. J Natl Cancer Inst. 1995. PMID: 7752255

3

[Prediction of carboplatin clearance from morphological and biological patient characteristics].

Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R, Canal P. Chatelut E, et al. Among authors: roche h. Bull Cancer. 1995 Nov;82(11):946-53. Bull Cancer. 1995. PMID: 8535021 French.

4

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Among authors: roche h. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

5

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.

Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roché H, Bugat R, Gonçalvès E, Mathieu-Boué A. Lokiec F, et al. Among authors: roche h. Cancer Chemother Pharmacol. 1995;36(1):79-82. doi: 10.1007/BF00685737. Cancer Chemother Pharmacol. 1995. PMID: 7720181

6

Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption.

Brunner V, Houyau P, Chatelut E, Roché H, Canal P. Brunner V, et al. Among authors: roche h. Cancer Chemother Pharmacol. 1995;35(4):352-3. doi: 10.1007/BF00689459. Cancer Chemother Pharmacol. 1995. PMID: 7828282 No abstract available.

7

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.

Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, Lafont T, Roché H. Puisset F, et al. Among authors: roche h. Cancer Chemother Pharmacol. 2007 Jul;60(2):305-8. doi: 10.1007/s00280-006-0385-4. Epub 2006 Nov 24. Cancer Chemother Pharmacol. 2007. PMID: 17124593

8

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, Canal P, Houin G. Chatelut E, et al. Among authors: roche h. J Pharm Sci. 1991 Aug;80(8):730-4. doi: 10.1002/jps.2600800804. J Pharm Sci. 1991. PMID: 1791530

9

Pharmacokinetics of high-dose i.v. alizapride in prevention of cisplatin-induced emesis.

Canal P, Roche H, Pasquier M, Bugat R, Berg D, Soula G, Carton M. Canal P, et al. Among authors: roche h. Fundam Clin Pharmacol. 1987;1(3):213-7. doi: 10.1111/j.1472-8206.1987.tb00559.x. Fundam Clin Pharmacol. 1987. PMID: 3428840

10

[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].

de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulié P, Roché H, Bugat R. de Forni M, et al. Among authors: roche h. Bull Cancer. 1993 May;80(5):408-17. Bull Cancer. 1993. PMID: 8173194 Clinical Trial. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

596 results

Search Page